• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci USA. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus

Giuseppe

Emeritus
[Source: PNAS, full text: (LINK). Abstract, edited.]

T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus


  1. Andrew S. Kondratowicz (a), Nicholas J. Lennemann<SUP> </SUP>(b), Patrick L. Sinn (b)<SUP> </SUP>, Robert A. Davey<SUP> </SUP>(c), Catherine L. Hunt (a), Sven Moller-Tank (a), David K. Meyerholz (d), Paul Rennert (e), Robert F. Mullins (f), Melinda Brindley (a,1), Lindsay M. Sandersfeld (a), Kathrina Quinn (c), Melodie Weller (g), Paul B. McCray, Jr. (b), John Chiorini (g), and Wendy Maury (a,2)
Author Affiliations: Departments of <SUP>a</SUP>Microbiology, <SUP>b</SUP>Pediatrics, <SUP>d</SUP>Pathology, and <SUP>f</SUP>Ophthalmology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242; <SUP>c</SUP>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555; <SUP>e</SUP>Biogen Idec, Cambridge, MA 02142; and <SUP>g</SUP>Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892

Edited* by Robert A. Lamb, Northwestern University, Evanston, IL, and approved April 7, 2011 (received for review December 21, 2010)


Abstract

The glycoproteins (GP) of enveloped viruses facilitate entry into the host cell by interacting with specific cellular receptors. Despite extensive study, a cellular receptor for the deadly filoviruses Ebolavirus and Marburgvirus has yet to be identified and characterized. Here, we show that T-cell Ig and mucin domain 1 (TIM-1) binds to the receptor binding domain of the Zaire Ebola virus (EBOV) glycoprotein, and ectopic TIM-1 expression in poorly permissive cells enhances EBOV infection by 10- to 30-fold. Conversely, reduction of cell-surface expression of TIM-1 by RNAi decreased infection of highly permissive Vero cells. TIM-1 expression within the human body is broader than previously appreciated, with expression on mucosal epithelia from the trachea, cornea, and conjunctiva?tissues believed to be important during in vivo transmission of filoviruses. Recognition that TIM-1 serves as a receptor for filoviruses on these mucosal epithelial surfaces provides a mechanistic understanding of routes of entry into the human body via inhalation of aerosol particles or hand-to-eye contact. ARD5, a monoclonal antibody against the IgV domain of TIM-1, blocked EBOV binding and infection, suggesting that antibodies or small molecules directed against this cellular receptor may provide effective filovirus antivirals.
Footnotes

  • <SUP>1</SUP>Present address: Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA 30322.
  • <SUP>2</SUP>To whom correspondence should be addressed. E-mail: wendy-maury@uiowa.edu.
  • Author contributions: A.S.K., N.J.L., P.L.S., R.A.D., D.K.M., P.B.M., J.C., and W.M. designed research; A.S.K., N.J.L., P.L.S., R.A.D., C.L.H., S.M.-T., D.K.M., M.B., L.M.S., K.Q., and W.M. performed research; P.R. and R.F.M. contributed new reagents/analytic tools; A.S.K., N.J.L., P.L.S., R.A.D., C.L.H., S.M.-T., D.K.M., R.F.M., L.M.S., K.Q., M.W., P.B.M., J.C., and W.M. analyzed data; and A.S.K., P.B.M., J.C., and W.M. wrote the paper.
  • The authors declare no conflict of interest.
  • *This Direct Submission article had a prearranged editor.
  • This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1019030108/-/DCSupplemental.
- -----
 
Back
Top